Increased levels of α-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 914-918

  Saraheimo, M ^a,b   Forsblom, C ^a,b   Pettersson Fernholm, K ^a,b   Flyvbjerg, A ^c   Groop, P H ^a,b,d   Frystyk, J ^c  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Blood lipids; Diabetic nephropathy; Low grade inflammation; defensin

Indexed keywords

ALBUMIN; ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 2; ALPHA DEFENSIN 3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; LIPID;

ADULT; AGE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS; ALBUMINURIA; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FINLAND; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL MODEL;

ADULT; ALBUMINURIA; ALPHA-DEFENSINS; BIOLOGICAL MARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FINLAND; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LINEAR MODELS; LIPIDS; MALE;

EID: 42449105382     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm711     Document Type: Article

References (25)

1. Orchard TJ, Chang Y, Ferrell RE et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 2002; 62: 963-970
2. Saraheimo M, Teppo AM, Forsblom C et al. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003; 46: 1402-1407
3. Hovind P, Hansen TK, Tarnow L et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes. Diabetes 2005; 54: 1523-1527
4. Saraheimo M, Forsblom C, Kansen TK et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005; 48: 198-202
5. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 2001; 58: 978-989
6. Niyonsaba F, Ushio H, Nagaoka I et al. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 2005; 175: 1776-1784
7. Schneider JJ, Unholzer A, Schaller M et al. Human defensins. J Mol Med 2005; 83: 587-595
8. Pazgier M, Hoover DM, Yang D et al. Human β-defensins. Cell Mol Life Sci 2006; 63: 1294-1313
9. Panuitich A, Ganz T. Activate α 2-macroglobulin is a principal defensin-binding protein. Am J Respir Cell Mol Biol 1991; 5: 101-106
10. James K, Merriman J, Gary RS et al. Serum a-macroglobulin levels in diabetes. J Clin Pathol 1980; 33: 163-166
11. Prohazska Z, Nemet K, Csermely P et al. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 and HIV-1. Mol Immunol 1997; 34: 809-816
12. Berg Van Den RH, Faber-Krol MC, Wetering van S et al. Inhibition of activation of classical pathway of complement by human neutrophil defensins. Blood 1998; 92: 3898-3903
13. Wetering van S, Mannesse-Lazeroms SPG, Dijkman JH et al. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol 1997; 62: 217-226
14. Chaly YV, Paleolog EM, Kolesnikova TS et al. Neutrophil α-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000; 11: 257-66
15. Higazi AA-R, Lavi E, Bdeir K et al. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997; 89: 4290-4298
16. Higazi AA-R, Nasar T, Ganz T et al. The α-defensins can stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and possible contributor to atherogenesis. Blood 2000; 96: 1393-1398
17. Nassar T, Akkawi S, Bar-Sawit R et al. Human α-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/α-2 macroglobulin receptor. Blood 2002; 100: 4026-4032
18. Williams KV, Erbey JR, Becker D et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000; 49: 626-632
19. Thorn LM, Forsblom C, Fagerudd J et al. Metabolic syndrome in type 1 diabetes. Diabetes Care 2005; 28; 2019-2024
20. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
21. Rubkin M, Ryan MP, Duckworth WC. Renal metabolism of insulin. Diabetologia 1987; 27: 351-357
22. Feld S, Hirschberg R. Growth hormone, the insulin like growth factor system, and the kidney. Endocr Rev 1996; 17: 423-480
23. Tuttle KR. Linking metabolism and Immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 2005; 16: 1537-1538
24. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002; 206: 9-18
25. Ashitani J, Nakazato M, Mukae H et al. Recombinant granulocyte colony-stimulating factor induces production of human neutrophil peptides in lung cancer patients with neutropenia. Regul Pept 2000; 95: 87-92